| European Case Law Identifier: | ECLI:EP:BA:2015:T051714.20150619 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 19 June 2015 | ||||||||
| Case number: | T 0517/14 | ||||||||
| Application number: | 08002626.3 | ||||||||
| IPC class: | A61K 31/663 A61P 19/10 C07F 9/38 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Crystalline form of ibandronate sodium | ||||||||
| Applicant name: | Teva Pharmaceutical Industries Ltd | ||||||||
| Opponent name: | Hexal AG Helm AG |
||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Right of priority - assignment Main request, allowable |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t140517eu1.html
Date retrieved: 17 May 2021